Autolus Therapeutics plc announced on September 16, 2025, the online publication of an abstract for the American College of Rheumatology (ACR) Convergence 2025. The company will present updated follow-up data from the CARLYSLE study in patients with severe refractory systemic lupus erythematosus (srSLE) in a poster presentation.
Initial findings from the ongoing CARLYSLE study of obe-cel in srSLE showed a manageable safety profile. The study reported no dose limiting toxicities (DLTs), immune effector cell-associated neurotoxicity syndrome (ICANS), or Grade ≥2 cytokine release syndrome (CRS).
Clinical benefit, including SLEDAI-2K score reduction, was observed in all patients, with three patients achieving a complete renal response. This further positive data reinforces the potential of obe-cel in autoimmune diseases, building on the company's strategic expansion into this high-unmet-need area.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.